A Mass Formula for EYM Solitons

The Isolated Horizon formalism, together with a simple phenomenological model for colored black holes was recently used to predict a formula for the ADM mass of the solitons of the EYM system in terms of horizon properties of black holes {\it for all} values of the horizon area. In this note, this formula is tested numerically --up to a large value of the area-- for spherically symmetric solutions and shown to yield the known masses of the solitonsComment: 8 pages, 1 table, no figures. Revtex file. Revised file. Added reference

A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol

© 2020, The Author(s). Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causative agent of coronavirus disease 2019 (COVID-19), may lead to severe systemic inflammatory response, pulmonary damage, and even acute respiratory distress syndrome (ARDS). This in turn may result in respiratory failure and in death. Experimentally, acetylcholine (ACh) modulates the acute inflammatory response, a neuro-immune mechanism known as the inflammatory reflex. Recent clinical evidence suggest that electrical and chemical stimulation of the inflammatory reflex may reduce the burden of inflammation in chronic inflammatory diseases. Pyridostigmine (PDG), an ACh-esterase inhibitor (i-ACh-e), increases the half-life of endogenous ACh, therefore mimicking the inflammatory reflex. This clinical trial is aimed at evaluating if add-on of PDG leads to a decrease of invasive mechanical ventilation and death among patients with severe COVID-19. Methods: A parallel-group, multicenter, randomized, double-blinded, placebo-controlled, phase 2/3 clinical trial to test the efficacy of pyridostigmine bromide 60 mg/day P.O. to reduce the need for invasive mechanical ventilation and mortality in hospitalized patients with severe COVID-19. Discussion: This study will provide preliminary evidence of whether or not -by decreasing systemic inflammation- add-on PDG can improve clinical outcomes in patients with severe COVID-19. Trial registration: ClinicalTrials.gov NCT04343963 (registered on April 14, 2020)

Opportunities and Challenges: Hepatitis C Testing and Treatment Access Experiences Among People in Methadone and Buprenorphine Treatment During COVID-19, Arizona, 2021

Introduction: The purpose of this study was to characterize hepatitis C virus screening and treatment access experiences among people in treatment for opioid use disorder in Arizona during COVID-19. Methods: Arizonans receiving treatment for opioid use disorder from methadone clinics and buprenorphine providers during COVID-19 were interviewed about hepatitis C virus testing, curative treatment, and knowledge about screening recommendations. Interviews were conducted with 121 people from August 4, 2021 to October 10, 2021. Qualitative data were coded using the categories of hepatitis C virus testing, knowledge of screening recommendations, diagnosis, and experiences seeking curative treatment. Data were also quantitated for bivariate testing with outcome variables of last hepatitis C virus test, diagnosis, and curative treatment process. Findings were arrayed along an adapted hepatitis C virus cascade framework to inform program and policy improvements. Results: Just over half of the sample reported ever having tested for hepatitis C virus (51.2%, n=62) and of this group, 58.1% were tested in the past 12 months. Among those who were ever tested, 54.8% reported a hepatitis C virus diagnosis and 16.1% reported either being in treatment or having been declared cured of the hepatitis C virus. Among those who were diagnosed with hepatitis C, 14.7% indicated that they unsuccessfully tried to access curative treatment and would not attempt to again. Reasons cited for not accessing or receiving curative treatment included beliefs about treatment safety, barriers created by access requirements, natural resolution of the infection, and issues with healthcare coverage and authorization. Conclusions: Structural barriers continue to prevent curative hepatitis C virus treatment access. Given that methadone and buprenorphine treatment providers serve patients who are largely undiagnosed or treated for hepatitis C virus, opportunities exist for them to screen their patients regularly and provide support for and/or navigation to hepatitis C virus curative treatment

Review and assessment of latent and sensible heat flux accuracy over the global oceans

For over a decade, several research groups have been developing air-sea heat flux information over the global ocean, including latent (LHF) and sensible (SHF) heat fluxes over the global ocean. This paper aims to provide new insight into the quality and error characteristics of turbulent heat flux estimates at various spatial and temporal scales (from daily upwards). The study is performed within the European Space Agency (ESA) Ocean Heat Flux (OHF) project. One of the main objectives of the OHF project is to meet the recommendations and requirements expressed by various international programs such as the World Research Climate Program (WCRP) and Climate and Ocean Variability, Predictability, and Change (CLIVAR), recognizing the need for better characterization of existing flux errors with respect to the input bulk variables (e.g. surface wind, air and sea surface temperatures, air and surface specific humidities), and to the atmospheric and oceanic conditions (e.g. wind conditions and sea state). The analysis is based on the use of daily averaged LHF and SHF and the asso- ciated bulk variables derived from major satellite-based and atmospheric reanalysis products. Inter-comparisons of heat flux products indicate that all of them exhibit similar space and time patterns. However, they also reveal significant differences in magnitude in some specific regions such as the western ocean boundaries during the Northern Hemisphere winter season, and the high southern latitudes. The differences tend to be closely related to large differences in surface wind speed and/or specific air humidity (for LHF) and to air and sea temperature differences (for SHF). Further quality investigations are performed through comprehensive comparisons with daily-averaged LHF and SHF estimated from moorings. The resulting statistics are used to assess the error of each OHF product. Consideration of error correlation between products and observations (e.g., by their assimilation) is also given. This reveals generally high noise variance in all products and a weak signal in common with in situ observations, with some products only slightly better than others. The OHF LHF and SHF products, and their associated error characteristics, are used to compute daily OHF multiproduct-ensemble (OHF/MPE) estimates of LHF and SHF over the ice-free global ocean on a 0.25° × 0.25° grid. The accuracy of this heat multiproduct, determined from comparisons with mooring data, is greater than for any individual product. It is used as a reference for the anomaly characterization of each individual OHF product

Options for agriculture at Marrakech climate talks: messages for SBSTA 45 agriculture negotiators

SBSTA 45 in Marrakech represents a unique opportunity for Parties to decide on the future of agriculture within the UNFCCC. The process of discussions on issues related to agriculture initiated at COP17 in Durban 2011 culminates at COP22 in Marrakech 2016. The explicit reference to food security in the preamble of the Paris Agreement and the Intended Nationally Determined Contributions which prioritize agriculture as a sector for adaptation and mitigation actions, provide a foundation for Parties to develop appropriate frameworks to support actions within the agricultural sector. SBSTA workshops on agriculture in 2015 and 2016 allowed Parties to share experiences, identify priorities, and propose ways of taking action within the agricultural sector and so provide the core knowledge base to work from. As Parties reach a decision on issues related to agriculture at SBSTA 45, a number of options are available. This report presents ten such options that might contribute to a decision, taking into consideration political priorities, implementation arrangements, timelines and level of ambition. Options outlined in this report are not mutually exclusive and can be combined in many different ways

Conceptual Framework for a Data Model to Support Asset Management Decision-Making Process

Part 4: Product and Asset Life Cycle Management in Smart Factories of Industry 4.0International audienceInformation and data management is nowadays a central issue to support the Asset Management (AM) decision-making process. Manufacturing companies have to take different decisions along the asset lifecycle and at different organisational levels, and, to this end, they require proper information and data management. In the literature, besides the crucial role played by information and data, there is evidence of existing gaps, especially related to information management and integration, and transformation of data into useful information. Thus, a conceptual framework is proposed to guide the definition of a data model to fulfil the previously identified gap. Generally, the framework aims at contributing to the improvement of the integration of information along the AM decision-making process. Specifically, it is intended to be aligned with the AM theory and, in particular, its fundamentals defined in the scientific literature and the ISO 5500x body of standards. Overall, thanks to the improvement of the information management and integration along with the AM decision-making, the expectation is to be capable of achieving more value-oriented decisions for the asset lifecycle

Bistability in Apoptosis by Receptor Clustering

Apoptosis is a highly regulated cell death mechanism involved in many physiological processes. A key component of extrinsically activated apoptosis is the death receptor Fas, which, on binding to its cognate ligand FasL, oligomerize to form the death-inducing signaling complex. Motivated by recent experimental data, we propose a mathematical model of death ligand-receptor dynamics where FasL acts as a clustering agent for Fas, which form locally stable signaling platforms through proximity-induced receptor interactions. Significantly, the model exhibits hysteresis, providing an upstream mechanism for bistability and robustness. At low receptor concentrations, the bistability is contingent on the trimerism of FasL. Moreover, irreversible bistability, representing a committed cell death decision, emerges at high concentrations, which may be achieved through receptor pre-association or localization onto membrane lipid rafts. Thus, our model provides a novel theory for these observed biological phenomena within the unified context of bistability. Importantly, as Fas interactions initiate the extrinsic apoptotic pathway, our model also suggests a mechanism by which cells may function as bistable life/death switches independently of any such dynamics in their downstream components. Our results highlight the role of death receptors in deciding cell fate and add to the signal processing capabilities attributed to receptor clustering.Comment: Accepted by PLoS Comput Bio

Miocene Climatic Optimum fungal record and plant-based CREST climatic reconstruction from southern McMurdo Sound, Antarctica

Deep-time palynological studies are necessary to evaluate plant and fungal distribution under warmer-than-present scenarios such as those of the Middle Miocene. Previous palynological studies from southern McMurdo Sound, Antarctica (SMS), have provided unique documentation for Neogene environments in the Ross Sea region during a time of pronounced global warming. The present study builds on these studies and provides a new climate reconstruction using the previously published SMS pollen and plant spore data. Additionally, 44 SMS samples were reanalyzed with a focus on the fungal fraction of the section to evaluate the fungal distribution under warmer than present conditions. The probability-based climate reconstruction technique (CREST) was applied to provide a new plant-based representation of regional paleoclimate for this Miocene Climatic Optimum (MCO) locality. CREST reconstructs a paleoclimate that is warmer and significantly wetter than present in SMS during the MCO, with mean annual precipitation reconstructed at 1147 mm yr−1 (95 % confidence range: 238–2611 mm yr−1) and a maximum mean annual temperature of 10.3 ∘C (95 % confidence range: 2.0–20.2 ∘C) for the warmest intervals of the MCO. The CREST reconstruction fits within the Cfb Köppen–Geiger climate class during the MCO of SMS. This new reconstruction agrees with previous reconstructions using various geochemical proxies. The fungal palynological analyses yielded surprising results, with only a single morphotype recovered, in low abundance, with concentrations ranging up to 199 fungi per gram of dried sediment. The taxa present belongs to the Apiosporaceae family and are known to be adapted to a wide range of climate and environmental conditions. As fungi are depauperate members of the SMS MCO palynofloras and because the one morphotype recovered is cosmopolitan, using the fungi record to confirm a narrow Köppen–Geiger climate class is impossible. Overall, the study demonstrates refinement of plant-based paleoclimatic reconstructions and sheds light on the limited presence of fungi during the MCO in Antarctica.</p

Treballs d'investigació en atenció primària: revisió dels treballs en llengües espanyoles publicats l'any 1986

Revisem 29 treballs elaborats per professionals d'atenció primària i publicats a: Atención Primaria, Medicina Clínica, Gaseta Sanitaria, Revista Clínica Española, Revista Española de Pediatría i Annals de Medicina. La majoria els trobem realitzats per especialistes o residents de Medicina Familiar i Comunitària, amb absència de pediatres. Entre els temes analitzats destaca l'anàlisi de la demanda, hipertensió arterial i vacunacions, que totalitzen quasi el 50% dels treballs. Cal ressaltar un 89% de dissenys descriptius, amb solament dos de tipus analític o experimental. Sobre 6 paràmetres d'adequació metodològica hi hagué un compliment mitjà de 4,38 (DE = 2,23). El 52% dels treballs no tenien tractament estadístic. Creiem que hi ha una extensa variabilitat en la qualitat deis treballs i que és necessari adaptar la temàtica d'interès deis investigadors i adaptar els dissenys a la demostració d'hipòtesis que suposin canvis en la pràctica assistencial

Tumor-Experienced Human NK Cells Express High Levels of PD-L1 and Inhibit CD8+ T Cell Proliferation

Natural Killer (NK) cells play a key role in cancer immunosurveillance. However, NK cells from cancer patients display an altered phenotype and impaired effector functions. In addition, evidence of a regulatory role for NK cells is emerging in diverse models of viral infection, transplantation, and autoimmunity. Here, we analyzed clear cell renal cell carcinoma (ccRCC) datasets from The Cancer Genome Atlas (TCGA) and observed that a higher expression of NK cell signature genes is associated with reduced survival. Analysis of fresh tumor samples from ccRCC patients unraveled the presence of a high frequency of tumor-infiltrating PD-L1+ NK cells, suggesting that these NK cells might exhibit immunoregulatory functions. In vitro, PD-L1 expression was induced on NK cells from healthy donors (HD) upon direct tumor cell recognition through NKG2D and was further up-regulated by monocyte-derived IL-18. Moreover, in vitro generated PD-L1hi NK cells displayed an activated phenotype and enhanced effector functions compared to PD-L1- NK cells, but simultaneously, they directly inhibited CD8+ T cell proliferation in a PD-L1-dependent manner. Our results suggest that tumors might drive the development of PD-L1-expressing NK cells that acquire immunoregulatory functions in humans. Hence, rational manipulation of these regulatory cells emerges as a possibility that may lead to improved anti-tumor immunity in cancer patients.Fil: Sierra, Jessica Mariel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Secchiari, Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Nuñez, Sol Yanel. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Raffo Iraolagoitia, Ximena Lucía. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Ziblat, Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Friedrich, Adrián David. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Cátedra de Inmunología; ArgentinaFil: Regge, María Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Santilli, Maria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Torres, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Gantov, Mariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Trotta, Aldana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Ameri, Carlos Enrique. Hospital Alemán; ArgentinaFil: Vitagliano, Gonzalo. Hospital Alemán; ArgentinaFil: Ríos Pita, Hernando. Hospital Alemán; ArgentinaFil: Rico, Luis. Hospital Alemán; ArgentinaFil: Rovegno, Agustín. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; ArgentinaFil: Richards, Nicolás. Centro de Educaciones Médicas e Investigación Clínica "Norberto Quirno"; ArgentinaFil: Domaica, Carolina Ines. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Zwirner, Norberto Walter. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Fuertes, Mercedes Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentin